The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5722-5732

  Gini, Beatrice ^a,c   Zanca, Ciro ^a   Guo, Deliang ⁱ   Matsutani, Tomoo ^a   Masui, Kenta ^a   Ikegami, Shiro ^a   Yang, Huijun ^a   Nathanson, David ^a   Villa, Genaro R ^a,g,h   Shackelford, David ^a   Zhu, Shaojun ^a   Tanaka, Kazuhiro ^a   Babic, Ivan ^a   Akhavan, David ^a   Lin, Kelly ^a   Assuncao, Alvaro ^a   Gu, Yuchao ^a,h   Bonetti, Bruno ^j   Mortensen, Deborah S ^d   Xu, Shuichan ^d   Raymon, Heather K ^d   Cavenee, Webster K ^a,b,c   Furnari, Frank B ^a,b,c   James, C David ^e   Kroemer, Guido ^k,l,m,n   Heath, James R ^f   Hege, Kristen ^d   Chopra, Rajesh ^d   Cloughesy, Timothy F ^g,h   Mischel, Paul S ^a,b,c   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CELGENE CORPORATION   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j UNIVERSITY OF VERONA   (Italy)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m CENTRE DE RECHERCHE DES CORDELIERS   (France)

ⁿ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CC 214 1; CC 214 2; CHLOROQUINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN EGFR8; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHAGY; CANCER INHIBITION; DNA LIBRARY; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; IMIDAZOLES; MULTIPROTEIN COMPLEXES; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; PYRAZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886422163     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0527     Document Type: Article

References (27)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710.
2. The Cancer Genome Atlas Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
3. Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, et al. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 2009;325:1261-5.
4. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
5. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo DL, Gini B, et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappa B pathway that promotes chemotherapy resistance. Cancer Discov 2011;1:524-38.
6. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008;5:e8.
7. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-304.
8. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008;105: 17414-9.
9. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012;485:109-13.
10. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, et al. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorg Med Chem Lett 2013;23:1588-91.
11. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov 2011;1:442-56.
12. Mortensen DS, Perrin-Ninkovic SM, Harris R, Lee BG, Shevlin G, Hickman M, et al. Discovery and SAR exploration of a novel series of imidazo[4,5-b] pyrazin-2-ones as potent and selective mTOR kinase inhibitors. Bioorg Med Chem Lett 2011;21:6793-9.
13. Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, et al. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci 2008;28:4406-13.
14. Lee M, Muller F, Aquilanti E, Hu B, DePinho R. Stereotactic orthotopic xenograft injections into the mouse brain. Protocol Exchange 2012 22 Aug.[Epub ahead of print]
15. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
16. Gini B, Lovato L, Cianti R, Cecotti L, Marconi S, Anghileri E, et al. Novel autoantigens recognized by CSF IgG from Hashimoto's encephalitis revealed by a proteomic approach. J Neuroimmunol 2008;196:153-8.
17. Bailey RC, Kwong GA, Radu CG, Witte ON, Heath JR. DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins. J Am Chem Soc 2007;129:1959-67.
18. Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med 2012;4:139ra84.
19. Kwong GA, Radu CG, Hwang K, Shu CJ,MaC, Koya RC, et al. Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc 2009;131:9695-703.
20. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6:1167-74.
21. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010;584:1287-95.
22. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011;25:460-70.
23. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, et al. Akt and autophagy cooperate to promote survival of drugresistant glioma. Sci Signal 2010;3:ra81.
24. Yecies JL, Manning BD. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res 2011;71:2815-20.
25. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284:8023-32.
26. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012;12:401-10.
27. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011;22:165-78.